Lung toxicity related to trimethoprim/sulfamethoxazole: pharmacovigilance data review
Journal of Antimicrobial Chemotherapy · 2025
DOI: 10.1093/jac/dkaf050 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von F Givry und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, University Hospital of Reims, Reims, France. Hauptthemen laut MEDLINE: Pharmacovigilance, Trimethoprim, Sulfamethoxazole Drug Combination, Anti-Bacterial Agents, Lung Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
Background
Well-established side effects of trimethoprim/sulfamethoxazole include cutaneous and liver toxicity, hypersensitivity syndrome and blood dyscrasias. Trimethoprim/sulfamethoxazole has also been associated with severe lung toxicity (LT) but reports are scarce.
Methods
We investigated pharmacovigilance data and reviewed spontaneous reports of trimethoprim/sulfamethoxazole-related LT recorded in the French national pharmacovigilance database (FPVD) and the WHO global database of adverse events (VigiBase®) up to 31 December 2023. We performed disproportionality analysis to detect a possible pharmacovigilance signal.
Results
A total of 755 patients with trimethoprim/sulfamethoxazole-related LT were reported in VigiBase®, 17 of which were from the FPVD. In VigiBase®, interstitial lung disease was the most frequent LT pattern (30.5%). A fatal outcome was reported in 197 patients (26.1%). Significant reporting ORs were observed for the following trimethoprim/sulfamethoxazole-related LT patterns: interstitial lung disease 1.5 (95% CI: 1.3–1.7); acute respiratory distress syndrome 2.9 (95% CI: 2.5–3.5); eosinophilic pneumonia 4.1 (95% CI: 3.2–5.2); diffuse alveolar damage 3.7 (95% CI: 2.6–5.3); organizing pneumonia 2.1 (95% CI: 1.4–3.1); pulmonary toxicity 1.9 (95% CI: 1.3–2.9); acute lung injury 7.5 (95% CI: 4.9–11.6) and hypersensitivity pneumonitis 2.7 (95% CI: 1.7–4.2).
Conclusions
We highlight statistically significant disproportionality for several trimethoprim/sulfamethoxazole-related LT patterns, which constitutes a pharmacovigilance signal. Trimethoprim/sulfamethoxazole-related LT is rare, but may be critical and even life-threatening. Physicians should be aware of potential trimethoprim/sulfamethoxazole-related LT and should inform their patients, since early intervention could prevent severe outcome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, University Hospital of Reims, Reims, France.
- Department of Respiratory Diseases, University Hospital of Reims, Reims, France.
- Department of Pharmacy, University Hospital of Reims, Reims, France.
- Department of Clinical Pharmacology, University Hospital, Nantes, France.
- Regional Centre for Pharmacovigilance and Pharmacoepidemiology, University Hospital of Reims, Reims, France.
- University of Reims Champagne Ardennes, INSERM, UMR-S1320 Cardiovir, Reims, France.
ORCID-Profile: M Hentzien, F Bani-Sadr
Zitieren
APA
Givry, F., Lebargy, F., Lebrun, D., Bonnet, M., Ruellan, A. L., Hentzien, M., Azzouz, B., & Bani-Sadr, F. (2025). Lung toxicity related to trimethoprim/sulfamethoxazole: pharmacovigilance data review. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf050
Vancouver
Givry F, Lebargy F, Lebrun D, Bonnet M, Ruellan AL, Hentzien M, et al. Lung toxicity related to trimethoprim/sulfamethoxazole: pharmacovigilance data review. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf050
BibTeX
@article{Givry2025,
author = {Givry, F and Lebargy, F and Lebrun, D and Bonnet, M and Ruellan, A L and Hentzien, M and Azzouz, B and Bani-Sadr, F},
title = {Lung toxicity related to trimethoprim/sulfamethoxazole: pharmacovigilance data review},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
doi = {10.1093/jac/dkaf050}
}
EUVIMED